# Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients

> **NCT00235651** · PHASE3 · TERMINATED · sponsor: **University of Pittsburgh** · enrollment: 12 (—)

## Conditions studied

- Lung Transplantation
- Lung Diseases

## Interventions

- **DRUG:** Amphotericin B

## Key facts

- **NCT ID:** NCT00235651
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** 2006-04
- **Target enrollment:** 12 (—)
- **Why stopped:** study completed
- **Last updated:** 2008-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00235651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00235651, "Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00235651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*